Stay updated on Reslizumab in EGPA: Clinical Trial

Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Reslizumab in EGPA: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dosage of the study medicine, reslizumab, given to participants in the treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA). This change may impact the efficacy and safety evaluation of the experimental drug in the study.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:35.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    29%
    Check dated 2024-05-22T20:32:20.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:53:24.000Z thumbnail image

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.